Total amount: € 0,00
Indexed/Abstracted in: EMBASE, Scopus
Online ISSN 1827-188X
Gupta A. K., Singhal S. K., Singh D. P.*, Panda N. K., Mann S. B. S., Sharma S. C.
From the Department of Otolaryngology Head and Neck Surgery and * Radiotherapy Postgraduate Institute of Medical Education and Research Chandigarh, India
Background. The overall survival rate for rhabdomyosarcoma (RMS) ranges from 20 to 70%. We want to share our experience in terms of survival rates by offering different therapeutic modalities for cases of RMS Head and Neck.
Methods. This is a prospective study on 50 cases of RMS managed at the Postgraduate Institute of Medical Education and Research, Chandigarh, India. The survival rates of all these cases are compared with different treatment protocols. Middle ear and mastoid was found to be the commonest site and facial nerve involvement was more common.
Results. Chemotherapy as a primary modality revealed 27.28% 3 years survival rates compared to chemotherapy and radiochemotherapy+radiotherapy and surgery respectively giving 50% and 66.6% 3 year survival rates respectively. The overall survival rate was found to be 50%. The prognosis was found to be poorer in cases with lymph node metastasis (14%) and cases with unusual histological features (16%).
Conclusions. Combined modality treatment using chemotherapy, local radiation therapy and surgery gives excellent results.